{"gene":"SHOX","run_date":"2026-06-10T07:46:31","timeline":{"discoveries":[{"year":1997,"finding":"SHOX (alias PHOG) encodes a homeodomain-containing transcription factor expressed at highest levels in osteogenic cells; the gene resides in the pseudoautosomal region PAR1 of the sex chromosomes and escapes X inactivation, establishing dosage-sensitive expression relevant to stature.","method":"Positional cloning, expression analysis in osteogenic cells, X-inactivation assay","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — positional cloning plus expression characterization in a single lab, multiple methods but no functional reconstitution","pmids":["9259282"],"is_preprint":false},{"year":2001,"finding":"SHOX protein localizes exclusively to the nucleus in multiple cell lines (U2Os, HEK293, COS7, NIH 3T3), and functions as a cell-type-specific transcriptional activator: transactivation of luciferase reporter constructs was detected only in the osteogenic U2Os line. C-terminally truncated SHOX proteins (as found in Leri-Weill syndrome patients) are inactive for target gene activation.","method":"Stable cell-line transfection, luciferase reporter assays, nuclear localization by immunofluorescence, truncation mutant analysis","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal reporter assays plus localization experiments, multiple cell lines, mutagenesis of disease-relevant truncations, single lab","pmids":["11751690"],"is_preprint":false},{"year":2003,"finding":"SHOX expression is regulated by a combination of transcriptional and translational control: an alternative internal promoter (P2) within exon 2 drives efficiently translated mRNA, while the upstream promoter (P1) produces mRNA with seven upstream AUG codons (uAUGs) that strongly inhibit translation. Site-directed mutagenesis of these uAUGs fully restores translation efficiency in cell lines and Xenopus embryos.","method":"Transient transfection of mono- and bicistronic reporters, in vitro translation assays, direct mRNA transfection, site-directed mutagenesis, Xenopus embryo injection","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro translation reconstitution plus mutagenesis and in vivo (Xenopus) validation, multiple orthogonal methods, single lab","pmids":["12960152"],"is_preprint":false},{"year":2004,"finding":"SHOX expression in osteogenic cell lines, primary oral fibroblasts, and primary chondrocytes induces cell cycle arrest and apoptosis, associated with altered expression of pRB, p53, p21(Cip1) and p27(Kip1). A disease-associated SHOX mutant (from Leri-Weill patients) does not exhibit these activities. Endogenous SHOX protein is predominantly expressed in hypertrophic/apoptotic chondrocytes of the human growth plate.","method":"Stable transfection in cell lines and primary cells, flow cytometry (cell cycle), apoptosis assays, Western blotting of cell cycle regulators, immunohistochemistry of human growth plate","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — loss-of-function-equivalent mutant comparison, multiple cell types, growth plate localization with functional consequence, single lab but multiple orthogonal methods","pmids":["15145945"],"is_preprint":false},{"year":2004,"finding":"The nuclear localization signal (NLS) of SHOX was mapped to a non-classic basic motif AKCRK in the recognition helix of the homeodomain. Fusion of this pentapeptide to a cytoplasmic reporter protein is sufficient to drive nuclear translocation. A disease-associated missense mutation R173C (C517T) abolishes nuclear entry; insertion of the NLS sequence adjacent to the mutant site restores translocation.","method":"Deletion mapping, NLS-reporter fusion constructs, immunofluorescence, mutagenesis of R173C, NLS rescue experiment","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 1 / Moderate — domain mapping by deletion, functional reconstitution with rescue mutagenesis, single lab, multiple orthogonal methods","pmids":["15173321"],"is_preprint":false},{"year":2005,"finding":"Nine homeodomain missense mutations found in ISS/LWD patients impair SHOX function through loss of DNA binding, reduced dimerization ability, and/or impaired nuclear translocation. One mutation (R153L) retains DNA binding, dimerization, and nuclear entry but is defective in transcriptional activation, defining a separable transactivation function.","method":"Electrophoretic mobility shift assay (DNA binding), co-immunoprecipitation (dimerization), immunofluorescence (nuclear translocation), luciferase reporter assay (transactivation), mutagenesis panel","journal":"Human mutation","confidence":"High","confidence_rationale":"Tier 1 / Moderate — multiple biochemical assays (EMSA, Co-IP, reporter) applied to nine independent mutations in a single systematic study","pmids":["15931687"],"is_preprint":false},{"year":2006,"finding":"In chicken limb buds, Shox expression is restricted to the central/proximal regions; it is repressed distally by FGF and BMP signals from the apical ectodermal ridge and proximally by retinoic acid signaling. Viral overexpression of Shox in chicken limbs consistently increases the length of skeletal elements, and micromass cultures show an initial increase in cartilage nodule number but failure to enlarge.","method":"In situ hybridization, retroviral overexpression in chicken embryos, micromass cultures, skeletal staining","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain-of-function in vivo with skeletal phenotype readout, pathway placement via signaling inhibition, single lab, multiple complementary methods","pmids":["16904661"],"is_preprint":false},{"year":2007,"finding":"NPPB (encoding BNP, natriuretic peptide B) is a direct transcriptional target of SHOX. SHOX transactivates the endogenous NPPB promoter in luciferase assays; chromatin immunoprecipitation (ChIP) confirmed SHOX binding to the NPPB promoter in vivo. Two LWD-associated SHOX mutants fail to activate the promoter. BNP and SHOX are co-expressed in late proliferative and hypertrophic chondrocytes of the human growth plate.","method":"Luciferase reporter assay with serial NPPB promoter deletions, chromatin immunoprecipitation (ChIP), mutant SHOX functional comparison, immunohistochemistry","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vivo ChIP plus reporter assay plus disease-mutant validation, single lab, multiple orthogonal methods","pmids":["17881654"],"is_preprint":false},{"year":2007,"finding":"Conserved non-coding elements (CNEs) located ~48–215 kb downstream of SHOX function as cis-regulatory enhancers active in the developing chicken limb bud; in ovo electroporation of GFP reporter constructs driven by individual CNEs demonstrated enhancer activity in three of eight tested elements. Deletion of this region in patients produces an LWD phenotype identical to SHOX coding mutations.","method":"In ovo electroporation enhancer assay in chicken limb bud (GFP reporter), comparative genomics, SNP/FISH mapping of patient deletions","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct in vivo enhancer assay with reporter, correlated with human disease deletions, single lab","pmids":["17200153"],"is_preprint":false},{"year":2009,"finding":"Three conserved non-coding elements upstream of SHOX have enhancer activity in the developing chicken limb bud (in ovo electroporation assay) but not in the developing cornea, defining tissue-specific upstream regulatory elements for SHOX.","method":"In ovo electroporation enhancer assay in chicken limb bud and cornea, comparative genomic analysis","journal":"European journal of human genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct in vivo enhancer assay, two tissue types tested, single lab","pmids":["19997128"],"is_preprint":false},{"year":2011,"finding":"SHOX physically interacts with the chondrogenic transcription factors SOX5 and SOX6, identified by yeast two-hybrid screen and confirmed by co-immunoprecipitation in human cells. The SHOX homeodomain and SOX6 HMG domain mediate the interaction. Disease-associated SHOX missense mutations disrupt the interaction. SHOX cooperates with SOX5/SOX6 and SOX9 to activate the upstream Agc1 (aggrecan) enhancer; SHOX mutations impair this cooperative activation.","method":"Yeast two-hybrid screen, co-immunoprecipitation, domain mapping, luciferase reporter assay (Agc1 enhancer), immunohistochemistry of human fetal growth plate, disease-mutant panel","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, domain mapping, functional reporter, disease-mutant validation, growth plate co-expression, multiple orthogonal methods","pmids":["21262861"],"is_preprint":false},{"year":2011,"finding":"SHOX activates FGFR3 promoter in luciferase reporter assays; ChIP-sequencing and EMSA demonstrated direct binding of SHOX to multiple upstream sequences of FGFR3. In chicken micromass cultures, viral overexpression of Shox negatively regulates Fgfr3 (quantitative RT-PCR and in situ hybridization), suggesting that SHOX represses FGFR3 in the mesomelic limb segments.","method":"Microarray analysis, luciferase reporter assay, ChIP-sequencing, EMSA, viral overexpression in chicken micromass cultures, qRT-PCR, in situ hybridization","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro binding (EMSA), ChIP-seq, functional reporter, and in vivo chicken model, single lab, multiple orthogonal methods","pmids":["21273290"],"is_preprint":false},{"year":2011,"finding":"Human SHOX and mouse Shox2 share functional redundancy in sinoatrial node (SAN) development: both show similar transcriptional repressive activity on the Nkx2.5 promoter in cell culture. In SHOX/Shox2 knock-in mice (Shox2 replaced by human SHOX), SAN formation and pacemaking function are fully restored, demonstrating that SHOX can repress Nkx2.5-driven SAN differentiation pathways.","method":"Luciferase reporter assay (Nkx2.5 promoter repression), SHOX/Shox2 knock-in mouse model, physiological/histological/molecular analysis of SAN","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — genetic knock-in rescue in vivo plus in vitro reporter assay, single lab but rigorous in vivo rescue design","pmids":["21454626"],"is_preprint":false},{"year":2011,"finding":"Alternative splicing coupled with nonsense-mediated RNA decay (NMD) regulates SHOX expression levels in a tissue- and time-specific manner. Inclusion of novel exon 2a introduces a premature stop codon leading to NMD; four novel exons (2a, 7-1, 7-2, 7-3) were identified. Exon 7 variants are exclusively expressed in fetal neural tissues.","method":"RT-PCR, RNA-Seq, functional analysis of exon 2a by minigene/NMD reporter, tissue expression profiling","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional NMD assay plus expression profiling across tissues, single lab","pmids":["21448463"],"is_preprint":false},{"year":2013,"finding":"SHOX triggers apoptosis via oxidative stress leading to lysosomal membrane rupture, release of active cathepsin B to the cytosol, mitochondrial membrane permeabilization, and caspase activation (intrinsic apoptotic pathway). LWD-associated mutants SHOX R153L and SHOX L185X (C-terminal truncation) do not induce oxidative stress or any of these downstream apoptotic events.","method":"ROS measurement, lysosomal integrity assays, cathepsin B activity assay, mitochondrial membrane potential assay, caspase activity assay, stable transfection of wild-type vs. mutant SHOX in U2OS cells","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mechanistic dissection of apoptotic pathway with multiple biochemical readouts, disease mutant validation, single lab","pmids":["24186869"],"is_preprint":false},{"year":2014,"finding":"In a Col2a1-SHOX transgenic mouse, human SHOXa regulates extracellular matrix gene expression during early limb development, including transcriptional activation of Ctgf (connective tissue growth factor). This was confirmed in human NHDF and U2OS cells and chicken micromass culture.","method":"Transgenic mouse (Col2a1-SHOX), quantitative and in situ hybridization analyses, confirmation in human cell lines and chicken micromass culture","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo transgenic model plus cell culture confirmation in multiple systems, single lab","pmids":["24887312"],"is_preprint":false},{"year":2014,"finding":"Zebrafish shox loss-of-function (morpholino knockdown) delays embryonic growth and markedly impairs calcification of the anterior vertebral column and craniofacial bones. The growth delay phenotype is rescued by co-overexpression of morpholino-resistant Shox mRNA, confirming specificity.","method":"Antisense morpholino knockdown in zebrafish, skeletal staining, mRNA rescue experiment","journal":"Developmental dynamics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo loss-of-function with rescue in zebrafish, single lab","pmids":["25483930"],"is_preprint":false},{"year":2016,"finding":"CYP26C1 (a retinoic acid catabolizing enzyme) is a genetic modifier of SHOX deficiency. CYP26C1 variants reduce its catabolic activity, elevating retinoic acid levels, which significantly decrease SHOX expression in human primary chondrocytes and zebrafish embryos. In zebrafish, individual morpholino knockdown of either shox or cyp26c1 shortens pectoral fins; combined knockdown produces a more severe phenotype, establishing epistasis.","method":"CYP26C1 enzymatic activity assay, SHOX expression in human primary chondrocytes with retinoic acid treatment, zebrafish morpholino knockdown (single and double), pectoral fin length measurement, family genetic co-segregation","journal":"EMBO molecular medicine","confidence":"High","confidence_rationale":"Tier 1 / Moderate — enzymatic assay, in vitro expression assay, genetic epistasis in vivo (zebrafish double knockdown), plus human family co-segregation, multiple orthogonal approaches","pmids":["27861128"],"is_preprint":false},{"year":2018,"finding":"A 563 bp enhancer downstream of SHOX drives specific expression in the zeugopodal limb regions where SHOX is required; a primary cell luciferase assay confirmed enhancer activity, and putative HOX binding sites within the conserved 100 bp core are required for its activity. This enhancer is removed in most non-coding PAR1 deletions that cause LWD.","method":"Transgenic mouse enhancer assay, luciferase reporter assay, HOX binding site mutagenesis, deletion mapping against LWD patient cohort","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vivo transgenic reporter plus mutagenesis of binding sites plus cell-based reporter, single lab","pmids":["30250174"],"is_preprint":false},{"year":2020,"finding":"5'UTR variants (c.-51G>A, c.-19G>A, c.-9del) reduce SHOX expression and contribute to haploinsufficiency. Luciferase assays showed c.-51G>A and c.-9del reduce activity at the post-transcriptional level; a minigene splicing assay demonstrated that c.-19G>A creates an aberrant branch site causing mis-splicing of SHOX mRNA.","method":"Luciferase reporter assay (5'UTR variants), luciferase mRNA quantification, minigene exon-trapping splicing assay","journal":"European journal of human genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional reporter plus splicing assay, two orthogonal methods, single lab","pmids":["32647378"],"is_preprint":false},{"year":2022,"finding":"WRN helicase domain directly regulates SHOX transcription by unwinding G-quadruplex structures in the SHOX locus. WRN-null zebrafish (wrn-/-) show impaired bone growth and shorter stature; shox-/- zebrafish exhibit the same phenotype; genetic overexpression of SHOX/shox rescues bone developmental deficiency in WRN/wrn-null animals both in vitro and in vivo.","method":"Zebrafish genetic knockout (wrn-/-, shox-/-), G-quadruplex unwinding assay (helicase assay), genetic rescue by SHOX overexpression in vitro and in vivo","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro helicase assay plus in vivo genetic epistasis rescue in zebrafish, multiple orthogonal methods, single lab","pmids":["36114168"],"is_preprint":false}],"current_model":"SHOX encodes a paired-related homeodomain transcription factor that resides in PAR1 of the sex chromosomes, localizes to the nucleus via an AKCRK NLS in its homeodomain recognition helix, and functions as a cell-type-specific transcriptional activator (and in some contexts repressor) regulating chondrocyte differentiation: it directly activates targets including BNP/NPPB, Agc1 (in cooperation with SOX5/SOX6/SOX9), CTGF, and FGFR3, while repressing Nkx2.5; in hypertrophic growth-plate chondrocytes it induces apoptosis via oxidative stress → lysosomal membrane permeabilization → cathepsin B release → intrinsic caspase pathway; its expression is controlled by dual promoters with upstream uAUG-mediated translational repression, by alternative splicing/NMD, by downstream and upstream cis-regulatory enhancers (including HOX-site-dependent elements), and by WRN helicase-mediated resolution of G-quadruplexes at the locus, with retinoic acid levels (modulated by CYP26C1) acting as a genetic modifier of SHOX expression level."},"narrative":{"mechanistic_narrative":"SHOX encodes a paired-related homeodomain transcription factor that governs chondrocyte differentiation and skeletal growth, residing in the pseudoautosomal region PAR1 where it escapes X-inactivation to give dosage-sensitive expression relevant to stature [PMID:9259282]. The protein localizes exclusively to the nucleus via a non-classic basic AKCRK motif in the homeodomain recognition helix, and functions as a cell-type-specific transcriptional activator whose disease-associated mutations impair DNA binding, dimerization, nuclear entry, or a separable transactivation function [PMID:11751690, PMID:15173321, PMID:15931687]. SHOX directly activates a chondrogenic target program, binding and transactivating the NPPB/BNP promoter, cooperating with SOX5/SOX6/SOX9 at the Agc1 (aggrecan) enhancer through a homeodomain–HMG-domain interaction, regulating FGFR3 and the extracellular-matrix gene Ctgf, and acting as a repressor of Nkx2.5 in sinoatrial node development — a role rescued by human SHOX in Shox2 knock-in mice [PMID:17881654, PMID:21262861, PMID:21273290, PMID:21454626, PMID:24887312]. In hypertrophic growth-plate chondrocytes, where endogenous SHOX is concentrated, it drives cell-cycle arrest and an intrinsic apoptotic program proceeding through oxidative stress, lysosomal membrane rupture, cathepsin B release, and caspase activation [PMID:15145945, PMID:24186869]. SHOX expression is itself tightly controlled by dual promoters with uAUG-mediated translational repression, alternative splicing coupled to NMD, downstream and upstream limb-specific enhancers requiring HOX binding sites, WRN-helicase resolution of locus G-quadruplexes, and retinoic acid levels set by the genetic modifier CYP26C1 [PMID:12960152, PMID:17200153, PMID:21448463, PMID:27861128, PMID:30250174, PMID:36114168]. Loss of SHOX function causes Leri-Weill dyschondrosteosis and idiopathic short stature, as established by recurrent coding and non-coding deletions and functionally null mutations [PMID:11751690, PMID:17200153, PMID:30250174].","teleology":[{"year":1997,"claim":"Established the identity and genomic context of SHOX, linking a homeodomain transcription factor in PAR1 that escapes X-inactivation to dosage-sensitive control of stature.","evidence":"Positional cloning, osteogenic expression analysis, and X-inactivation assay","pmids":["9259282"],"confidence":"Medium","gaps":["No target genes or biochemical activity defined","Functional reconstitution absent"]},{"year":2001,"claim":"Showed SHOX is a nuclear, cell-type-restricted transcriptional activator and that Leri-Weill truncations abolish target activation, tying the protein's transactivation to disease.","evidence":"Luciferase reporter assays, immunofluorescence, and truncation mutant analysis across multiple cell lines","pmids":["11751690"],"confidence":"High","gaps":["Direct target genes not yet identified","Basis of cell-type specificity unresolved"]},{"year":2003,"claim":"Defined translational and promoter-level control: a P2 promoter yields efficiently translated mRNA whereas P1 transcripts are repressed by upstream AUG codons.","evidence":"Reporter and in vitro translation assays with uAUG mutagenesis, validated in Xenopus embryos","pmids":["12960152"],"confidence":"High","gaps":["Physiological trigger selecting promoter/translation usage unknown"]},{"year":2004,"claim":"Connected SHOX to growth-plate biology by showing it drives cell-cycle arrest and apoptosis in chondrocytes and is concentrated in hypertrophic chondrocytes.","evidence":"Stable transfection, flow cytometry, apoptosis assays, cell-cycle regulator Westerns, and growth-plate IHC, with disease-mutant comparison","pmids":["15145945"],"confidence":"High","gaps":["Molecular pathway from SHOX to apoptosis not yet defined","Direct apoptotic target genes unknown"]},{"year":2004,"claim":"Mapped the nuclear localization signal to the AKCRK motif in the recognition helix and showed a disease mutation (R173C) blocks nuclear entry, explaining one mutational mechanism.","evidence":"Deletion mapping, NLS-reporter fusions, immunofluorescence, and rescue mutagenesis","pmids":["15173321"],"confidence":"High","gaps":["Import receptor mediating non-classic NLS recognition unidentified"]},{"year":2005,"claim":"Systematically resolved how homeodomain mutations cause haploinsufficiency — via lost DNA binding, dimerization, or nuclear entry — and isolated a transactivation-specific defect (R153L).","evidence":"EMSA, co-immunoprecipitation, immunofluorescence, and reporter assays across nine patient mutations","pmids":["15931687"],"confidence":"High","gaps":["Transactivation cofactors at R153L-affected step not identified"]},{"year":2006,"claim":"Placed Shox in limb patterning, showing its expression is bounded by FGF/BMP and retinoic acid signals and that overexpression lengthens skeletal elements.","evidence":"In situ hybridization, retroviral overexpression, and micromass culture in chicken","pmids":["16904661"],"confidence":"Medium","gaps":["Direct transcriptional targets mediating elongation not defined","Mammalian relevance not addressed"]},{"year":2007,"claim":"Identified NPPB/BNP as a direct SHOX target, providing the first validated transcriptional target with growth-plate co-expression.","evidence":"Promoter-deletion luciferase assays, ChIP, disease-mutant comparison, and IHC","pmids":["17881654"],"confidence":"High","gaps":["Role of BNP induction in chondrocyte fate not functionally tested"]},{"year":2007,"claim":"Demonstrated that downstream conserved non-coding elements act as limb enhancers and that their deletion phenocopies coding mutations, defining non-coding disease mechanisms.","evidence":"In ovo electroporation enhancer assays and mapping of patient deletions","pmids":["17200153"],"confidence":"High","gaps":["Trans-factors binding the enhancers not identified"]},{"year":2009,"claim":"Extended the regulatory landscape upstream, showing tissue-specific upstream enhancers active in limb but not cornea.","evidence":"In ovo electroporation enhancer assays in two tissues","pmids":["19997128"],"confidence":"Medium","gaps":["Endogenous contribution and bound factors undetermined"]},{"year":2011,"claim":"Revealed how SHOX is integrated into the chondrogenic network, physically partnering with SOX5/SOX6 and cooperating with SOX9 to activate the Agc1 enhancer.","evidence":"Yeast two-hybrid, reciprocal Co-IP, domain mapping, Agc1 reporter, IHC, and disease-mutant panel","pmids":["21262861"],"confidence":"High","gaps":["Genome-wide co-occupancy with SOX factors not mapped"]},{"year":2011,"claim":"Established FGFR3 as a directly bound SHOX target, linking SHOX to a key growth-plate signaling receptor in mesomelic segments.","evidence":"Microarray, reporter assay, ChIP-seq, EMSA, and chicken micromass overexpression","pmids":["21273290"],"confidence":"High","gaps":["Activation versus repression context dependence not fully resolved"]},{"year":2011,"claim":"Showed SHOX represses Nkx2.5 and is functionally interchangeable with Shox2 in sinoatrial node development, defining a repressor activity and conserved function outside the skeleton.","evidence":"Nkx2.5 reporter repression assay and SHOX/Shox2 knock-in mouse rescue","pmids":["21454626"],"confidence":"High","gaps":["Whether native human SHOX functions in cardiac tissue physiologically untested"]},{"year":2011,"claim":"Added post-transcriptional control by alternative splicing coupled to NMD, including a tissue-specific exon 2a that triggers decay.","evidence":"RT-PCR, RNA-Seq, minigene/NMD reporter, and tissue profiling","pmids":["21448463"],"confidence":"Medium","gaps":["Regulatory inputs controlling splice-choice not identified"]},{"year":2013,"claim":"Dissected the SHOX apoptotic pathway as oxidative stress → lysosomal rupture → cathepsin B release → mitochondrial permeabilization → caspase activation, with disease mutants failing at the first step.","evidence":"ROS, lysosomal integrity, cathepsin B, mitochondrial potential, and caspase assays with WT vs mutant SHOX in U2OS","pmids":["24186869"],"confidence":"High","gaps":["SHOX transcriptional targets that initiate oxidative stress unknown"]},{"year":2014,"claim":"Identified Ctgf as a SHOX-regulated extracellular matrix gene in vivo, broadening the target repertoire to ECM organization.","evidence":"Col2a1-SHOX transgenic mouse with confirmation in human cells and chicken micromass","pmids":["24887312"],"confidence":"Medium","gaps":["Direct versus indirect regulation of Ctgf not distinguished"]},{"year":2014,"claim":"Confirmed an evolutionarily conserved requirement for shox in skeletal calcification through loss-of-function in zebrafish.","evidence":"Morpholino knockdown with mRNA rescue and skeletal staining","pmids":["25483930"],"confidence":"Medium","gaps":["Morpholino-only knockdown without genetic mutant"]},{"year":2016,"claim":"Defined CYP26C1 as a genetic modifier acting through retinoic acid, where reduced RA catabolism lowers SHOX expression and worsens skeletal phenotypes.","evidence":"Enzymatic assays, RA treatment of human chondrocytes, zebrafish single/double knockdown epistasis, and family co-segregation","pmids":["27861128"],"confidence":"High","gaps":["Transcription factors transducing RA signal onto SHOX promoter unidentified"]},{"year":2018,"claim":"Localized a 563 bp downstream limb enhancer whose HOX binding sites are required and whose loss in PAR1 deletions causes LWD, refining the regulatory disease map.","evidence":"Transgenic mouse and cell reporter assays, HOX-site mutagenesis, and deletion mapping in patients","pmids":["30250174"],"confidence":"High","gaps":["Specific HOX factors binding the core not identified"]},{"year":2020,"claim":"Showed 5'UTR variants reduce SHOX expression post-transcriptionally or via aberrant splicing, expanding mechanisms of haploinsufficiency.","evidence":"Luciferase reporter, mRNA quantification, and minigene splicing assays","pmids":["32647378"],"confidence":"Medium","gaps":["Endogenous quantitative impact on stature not measured"]},{"year":2022,"claim":"Linked WRN helicase to SHOX transcription by resolving locus G-quadruplexes, with SHOX overexpression rescuing WRN-null skeletal defects, placing SHOX downstream of WRN in bone growth.","evidence":"In vitro G-quadruplex unwinding assay and zebrafish wrn-/-, shox-/- epistasis with genetic rescue","pmids":["36114168"],"confidence":"High","gaps":["Whether WRN-SHOX axis operates in human growth plate not shown"]},{"year":null,"claim":"How SHOX selects between activator and repressor modes, and the full identity of its cofactor-dependent target program in human hypertrophic chondrocytes, remains unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No genome-wide SHOX occupancy map in human chondrocytes","Switch between transactivation and repression not mechanistically defined","Apoptosis-initiating target genes unidentified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[1,7,10,11,12]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[5,7,11]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1,4]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[7,11,12]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[6,8,16,18]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[3,14]}],"complexes":[],"partners":["SOX5","SOX6","SOX9"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O15266","full_name":"Short stature homeobox protein","aliases":["Pseudoautosomal homeobox-containing osteogenic protein","Short stature homeobox-containing protein"],"length_aa":292,"mass_kda":32.2,"function":"Transcription factor that controls fundamental aspects of growth. Directly activates NPPB transcription in osteogenic cells (PubMed:11751690, PubMed:17881654). Preferentially binds DNA elements with the sequence 5'-TAATNNNATTA-3', possibly as a homodimer (PubMed:11751690)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/O15266/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SHOX","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":74,"dependency_fraction":0.013513513513513514},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SHOX","total_profiled":1310},"omim":[{"mim_id":"608428","title":"CYTOCHROME P450, SUBFAMILY XXVIC, POLYPEPTIDE 1; CYP26C1","url":"https://www.omim.org/entry/608428"},{"mim_id":"606255","title":"STATURE AS A QUANTITATIVE TRAIT","url":"https://www.omim.org/entry/606255"},{"mim_id":"602504","title":"SHORT STATURE HOMEOBOX 2; SHOX2","url":"https://www.omim.org/entry/602504"},{"mim_id":"600571","title":"RE1-SILENCING TRANSCRIPTION FACTOR; REST","url":"https://www.omim.org/entry/600571"},{"mim_id":"600296","title":"NATRIURETIC PEPTIDE PRECURSOR C; NPPC","url":"https://www.omim.org/entry/600296"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"},{"location":"Vesicles","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in single","driving_tissues":[],"url":"https://www.proteinatlas.org/search/SHOX"},"hgnc":{"alias_symbol":["PHOG","GCFX","SS","SHOXY","SHOX1"],"prev_symbol":[]},"alphafold":{"accession":"O15266","domains":[{"cath_id":"1.10.10.60","chopping":"127-181","consensus_level":"high","plddt":94.5285,"start":127,"end":181}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O15266","model_url":"https://alphafold.ebi.ac.uk/files/AF-O15266-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O15266-F1-predicted_aligned_error_v6.png","plddt_mean":62.47},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SHOX","jax_strain_url":"https://www.jax.org/strain/search?query=SHOX"},"sequence":{"accession":"O15266","fasta_url":"https://rest.uniprot.org/uniprotkb/O15266.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O15266/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O15266"}},"corpus_meta":[{"pmid":"10749976","id":"PMC_10749976","title":"The short stature homeobox gene SHOX is involved in skeletal abnormalities in Turner syndrome.","date":"2000","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10749976","citation_count":344,"is_preprint":false},{"pmid":"9590292","id":"PMC_9590292","title":"SHOX mutations in dyschondrosteosis (Leri-Weill syndrome).","date":"1998","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9590292","citation_count":276,"is_preprint":false},{"pmid":"9590293","id":"PMC_9590293","title":"Mutation and deletion of the pseudoautosomal gene SHOX cause Leri-Weill dyschondrosteosis.","date":"1998","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9590293","citation_count":251,"is_preprint":false},{"pmid":"9259282","id":"PMC_9259282","title":"PHOG, a candidate gene for involvement in the short stature of Turner syndrome.","date":"1997","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9259282","citation_count":228,"is_preprint":false},{"pmid":"17182655","id":"PMC_17182655","title":"Genotypes and phenotypes in children with short stature: clinical indicators of SHOX haploinsufficiency.","date":"2006","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17182655","citation_count":179,"is_preprint":false},{"pmid":"21325865","id":"PMC_21325865","title":"Short stature due to SHOX deficiency: genotype, phenotype, and therapy.","date":"2011","source":"Hormone research in paediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/21325865","citation_count":168,"is_preprint":false},{"pmid":"11889216","id":"PMC_11889216","title":"Deletions of the homeobox gene SHOX (short stature homeobox) are an important cause of growth failure in children with short stature.","date":"2002","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/11889216","citation_count":155,"is_preprint":false},{"pmid":"11739418","id":"PMC_11739418","title":"Phenotypes Associated with SHOX Deficiency.","date":"2001","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/11739418","citation_count":146,"is_preprint":false},{"pmid":"16597678","id":"PMC_16597678","title":"High incidence of SHOX anomalies in individuals with short stature.","date":"2006","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16597678","citation_count":107,"is_preprint":false},{"pmid":"16175500","id":"PMC_16175500","title":"A novel class of Pseudoautosomal region 1 deletions downstream of SHOX is associated with Leri-Weill dyschondrosteosis.","date":"2005","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16175500","citation_count":104,"is_preprint":false},{"pmid":"16650979","id":"PMC_16650979","title":"The pseudoautosomal regions, SHOX and disease.","date":"2006","source":"Current opinion in genetics & development","url":"https://pubmed.ncbi.nlm.nih.gov/16650979","citation_count":103,"is_preprint":false},{"pmid":"27355317","id":"PMC_27355317","title":"A Track Record on SHOX: From Basic Research to Complex Models and Therapy.","date":"2016","source":"Endocrine reviews","url":"https://pubmed.ncbi.nlm.nih.gov/27355317","citation_count":101,"is_preprint":false},{"pmid":"19578035","id":"PMC_19578035","title":"Enhancer deletions of the SHOX gene as a frequent cause of short stature: the essential role of a 250 kb downstream regulatory domain.","date":"2009","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19578035","citation_count":101,"is_preprint":false},{"pmid":"9482898","id":"PMC_9482898","title":"SHOT, a SHOX-related homeobox gene, is implicated in craniofacial, brain, heart, and limb development.","date":"1998","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9482898","citation_count":100,"is_preprint":false},{"pmid":"17200153","id":"PMC_17200153","title":"Long-range conserved non-coding SHOX sequences regulate expression in developing chicken limb and are associated with short stature phenotypes in human patients.","date":"2007","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17200153","citation_count":94,"is_preprint":false},{"pmid":"11134233","id":"PMC_11134233","title":"SHOX haploinsufficiency and overdosage: impact of gonadal function status.","date":"2001","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11134233","citation_count":93,"is_preprint":false},{"pmid":"15145945","id":"PMC_15145945","title":"The short stature homeodomain protein SHOX induces cellular growth arrest and apoptosis and is expressed in human growth plate chondrocytes.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15145945","citation_count":86,"is_preprint":false},{"pmid":"17201812","id":"PMC_17201812","title":"SHOX mutations in idiopathic short stature and Leri-Weill dyschondrosteosis: frequency and phenotypic variability.","date":"2007","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/17201812","citation_count":84,"is_preprint":false},{"pmid":"11751690","id":"PMC_11751690","title":"The Leri-Weill and Turner syndrome homeobox gene SHOX encodes a cell-type specific transcriptional activator.","date":"2001","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11751690","citation_count":83,"is_preprint":false},{"pmid":"12116254","id":"PMC_12116254","title":"Complete SHOX deficiency causes Langer mesomelic dysplasia.","date":"2002","source":"American journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12116254","citation_count":81,"is_preprint":false},{"pmid":"10634394","id":"PMC_10634394","title":"Identification of short stature caused by SHOX defects and therapeutic effect of recombinant human growth hormone.","date":"2000","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/10634394","citation_count":77,"is_preprint":false},{"pmid":"27194967","id":"PMC_27194967","title":"SHOX Haploinsufficiency as a Cause of Syndromic and Nonsyndromic Short Stature.","date":"2016","source":"Molecular syndromology","url":"https://pubmed.ncbi.nlm.nih.gov/27194967","citation_count":72,"is_preprint":false},{"pmid":"15292358","id":"PMC_15292358","title":"Expression of SHOX in human fetal and childhood growth plate.","date":"2004","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/15292358","citation_count":70,"is_preprint":false},{"pmid":"15356038","id":"PMC_15356038","title":"SHOX haploinsufficiency and Leri-Weill dyschondrosteosis: prevalence and growth failure in relation to mutation, sex, and degree of wrist deformity.","date":"2004","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/15356038","citation_count":60,"is_preprint":false},{"pmid":"20847698","id":"PMC_20847698","title":"SHOX duplications found in some cases with type I Mayer-Rokitansky-Kuster-Hauser syndrome.","date":"2010","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20847698","citation_count":57,"is_preprint":false},{"pmid":"19435885","id":"PMC_19435885","title":"Berkeley PHOG: PhyloFacts orthology group prediction web server.","date":"2009","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/19435885","citation_count":53,"is_preprint":false},{"pmid":"10878753","id":"PMC_10878753","title":"SHOX: growth, Léri-Weill and Turner syndromes.","date":"2000","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/10878753","citation_count":51,"is_preprint":false},{"pmid":"22572840","id":"PMC_22572840","title":"IGF1, IGF1R and SHOX mutation analysis in short children born small for gestational age and short children with normal birth size (idiopathic short stature).","date":"2012","source":"Hormone research in paediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/22572840","citation_count":51,"is_preprint":false},{"pmid":"22518848","id":"PMC_22518848","title":"Genotypes and phenotypes of children with SHOX deficiency in France.","date":"2012","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/22518848","citation_count":49,"is_preprint":false},{"pmid":"16464624","id":"PMC_16464624","title":"The Aspergillus nidulans xprG (phoG) gene encodes a putative transcriptional activator involved in the response to nutrient limitation.","date":"2006","source":"Fungal genetics and biology : FG & B","url":"https://pubmed.ncbi.nlm.nih.gov/16464624","citation_count":47,"is_preprint":false},{"pmid":"12960152","id":"PMC_12960152","title":"Transcriptional and translational regulation of the Leri-Weill and Turner syndrome homeobox gene SHOX.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12960152","citation_count":47,"is_preprint":false},{"pmid":"21262861","id":"PMC_21262861","title":"SHOX interacts with the chondrogenic transcription factors SOX5 and SOX6 to activate the aggrecan enhancer.","date":"2011","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21262861","citation_count":46,"is_preprint":false},{"pmid":"17881654","id":"PMC_17881654","title":"BNP is a transcriptional target of the short stature homeobox gene SHOX.","date":"2007","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17881654","citation_count":44,"is_preprint":false},{"pmid":"19533800","id":"PMC_19533800","title":"Clinical and molecular characterization of duplications encompassing the human SHOX gene reveal a variable effect on stature.","date":"2009","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/19533800","citation_count":44,"is_preprint":false},{"pmid":"21454626","id":"PMC_21454626","title":"Functional redundancy between human SHOX and mouse Shox2 genes in the regulation of sinoatrial node formation and pacemaking function.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21454626","citation_count":43,"is_preprint":false},{"pmid":"24296787","id":"PMC_24296787","title":"The sitting height/height ratio for age in healthy and short individuals and its potential role in selecting short children for SHOX analysis.","date":"2013","source":"Hormone research in paediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/24296787","citation_count":43,"is_preprint":false},{"pmid":"16227037","id":"PMC_16227037","title":"The phenotype of short stature homeobox gene (SHOX) deficiency in childhood: contrasting children with Leri-Weill dyschondrosteosis and Turner syndrome.","date":"2005","source":"The Journal of pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/16227037","citation_count":43,"is_preprint":false},{"pmid":"22071895","id":"PMC_22071895","title":"Identification of the first PAR1 deletion encompassing upstream SHOX enhancers in a family with idiopathic short stature.","date":"2011","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/22071895","citation_count":41,"is_preprint":false},{"pmid":"21448463","id":"PMC_21448463","title":"Alternative splicing and nonsense-mediated RNA decay contribute to the regulation of SHOX expression.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21448463","citation_count":39,"is_preprint":false},{"pmid":"19997128","id":"PMC_19997128","title":"Enhancer elements upstream of the SHOX gene are active in the developing limb.","date":"2009","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/19997128","citation_count":39,"is_preprint":false},{"pmid":"21273290","id":"PMC_21273290","title":"FGFR3 is a target of the homeobox transcription factor SHOX in limb development.","date":"2011","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21273290","citation_count":39,"is_preprint":false},{"pmid":"16941489","id":"PMC_16941489","title":"PAR1 deletions downstream of SHOX are the most frequent defect in a Spanish cohort of Léri-Weill dyschondrosteosis (LWD) probands.","date":"2006","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/16941489","citation_count":39,"is_preprint":false},{"pmid":"11735031","id":"PMC_11735031","title":"Analysis of short stature homeobox-containing gene ( SHOX) and auxological phenotype in dyschondrosteosis and isolated Madelung deformity.","date":"2001","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11735031","citation_count":37,"is_preprint":false},{"pmid":"22020182","id":"PMC_22020182","title":"SHOX gene defects and selected dysmorphic signs in patients of idiopathic short stature and Léri-Weill dyschondrosteosis.","date":"2011","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/22020182","citation_count":36,"is_preprint":false},{"pmid":"15931687","id":"PMC_15931687","title":"Alteration of DNA binding, dimerization, and nuclear translocation of SHOX homeodomain mutations identified in idiopathic short stature and Leri-Weill dyschondrosteosis.","date":"2005","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/15931687","citation_count":35,"is_preprint":false},{"pmid":"16904661","id":"PMC_16904661","title":"Expression of the short stature homeobox gene Shox is restricted by proximal and distal signals in chick limb buds and affects the length of skeletal elements.","date":"2006","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/16904661","citation_count":35,"is_preprint":false},{"pmid":"17922307","id":"PMC_17922307","title":"SHOX at a glance: from gene to protein.","date":"2007","source":"Archives of physiology and biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17922307","citation_count":33,"is_preprint":false},{"pmid":"26040210","id":"PMC_26040210","title":"Rare pseudoautosomal copy-number variations involving SHOX and/or its flanking regions in individuals with and without short stature.","date":"2015","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26040210","citation_count":32,"is_preprint":false},{"pmid":"11030412","id":"PMC_11030412","title":"Mutations in short stature homeobox containing gene (SHOX) in dyschondrosteosis but not in hypochondroplasia.","date":"2000","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11030412","citation_count":32,"is_preprint":false},{"pmid":"21925981","id":"PMC_21925981","title":"The role of the SHOX gene in the pathophysiology of Turner syndrome.","date":"2011","source":"Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion","url":"https://pubmed.ncbi.nlm.nih.gov/21925981","citation_count":31,"is_preprint":false},{"pmid":"17091221","id":"PMC_17091221","title":"Identification and characterization of different SHOX gene deletions in patients with Leri-Weill dyschondrosteosys by MLPA assay.","date":"2006","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17091221","citation_count":30,"is_preprint":false},{"pmid":"27073233","id":"PMC_27073233","title":"Microduplications at the pseudoautosomal SHOX locus in autism spectrum disorders and related neurodevelopmental conditions.","date":"2016","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27073233","citation_count":29,"is_preprint":false},{"pmid":"15173321","id":"PMC_15173321","title":"Impairment of SHOX nuclear localization as a cause for Léri-Weill syndrome.","date":"2004","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/15173321","citation_count":28,"is_preprint":false},{"pmid":"25110390","id":"PMC_25110390","title":"Skeletal Deformity Associated with SHOX Deficiency.","date":"2014","source":"Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/25110390","citation_count":27,"is_preprint":false},{"pmid":"24186869","id":"PMC_24186869","title":"SHOX triggers the lysosomal pathway of apoptosis via oxidative stress.","date":"2013","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24186869","citation_count":27,"is_preprint":false},{"pmid":"10549307","id":"PMC_10549307","title":"SHOX: pseudoautosomal homeobox containing gene for short stature and dyschondrosteosis.","date":"1999","source":"Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/10549307","citation_count":26,"is_preprint":false},{"pmid":"16007631","id":"PMC_16007631","title":"Microdeletion in the SHOX 3' region associated with skeletal phenotypes of Langer mesomelic dysplasia in a 45,X/46,X,r(X) infant and Leri-Weill dyschondrosteosis in her 46,XX mother: implication for the SHOX enhancer.","date":"2005","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/16007631","citation_count":26,"is_preprint":false},{"pmid":"16807223","id":"PMC_16807223","title":"Short stature and dysmorphology associated with defects in the SHOX gene.","date":"2006","source":"Hormones (Athens, Greece)","url":"https://pubmed.ncbi.nlm.nih.gov/16807223","citation_count":25,"is_preprint":false},{"pmid":"12116253","id":"PMC_12116253","title":"Pseudodominant inheritance of Langer mesomelic dysplasia caused by a SHOX homeobox missense mutation.","date":"2002","source":"American journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12116253","citation_count":25,"is_preprint":false},{"pmid":"23666967","id":"PMC_23666967","title":"Prepubertal girls with Turner syndrome and children with isolated SHOX deficiency have similar bone geometry at the radius.","date":"2013","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/23666967","citation_count":25,"is_preprint":false},{"pmid":"27207956","id":"PMC_27207956","title":"Large Deletions at the SHOX Locus in the Pseudoautosomal Region Are Associated with Skeletal Atavism in Shetland Ponies.","date":"2016","source":"G3 (Bethesda, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/27207956","citation_count":25,"is_preprint":false},{"pmid":"26984564","id":"PMC_26984564","title":"Systematic molecular analyses of SHOX in Japanese patients with idiopathic short stature and Leri-Weill dyschondrosteosis.","date":"2016","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26984564","citation_count":24,"is_preprint":false},{"pmid":"12035792","id":"PMC_12035792","title":"Trisomy of the short stature homeobox-containing gene (SHOX), resulting from a duplication-deletion of the X chromosome.","date":"2002","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/12035792","citation_count":24,"is_preprint":false},{"pmid":"10507731","id":"PMC_10507731","title":"Loss of the SHOX gene associated with Leri-Weill dyschondrosteosis in a 45,X male.","date":"1999","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10507731","citation_count":24,"is_preprint":false},{"pmid":"11523902","id":"PMC_11523902","title":"Growth hormone and gonadotropin-releasing hormone analog therapy in haploinsufficiency of SHOX.","date":"2001","source":"Endocrine journal","url":"https://pubmed.ncbi.nlm.nih.gov/11523902","citation_count":24,"is_preprint":false},{"pmid":"26698168","id":"PMC_26698168","title":"Duplications upstream and downstream of SHOX identified as novel causes of Leri-Weill dyschondrosteosis or idiopathic short stature.","date":"2015","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/26698168","citation_count":23,"is_preprint":false},{"pmid":"21731768","id":"PMC_21731768","title":"Functional analysis of conserved non-coding regions around the short stature hox gene (shox) in whole zebrafish embryos.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21731768","citation_count":23,"is_preprint":false},{"pmid":"14513875","id":"PMC_14513875","title":"Familial growth and skeletal features associated with SHOX haploinsufficiency.","date":"2003","source":"Journal of pediatric endocrinology & metabolism : JPEM","url":"https://pubmed.ncbi.nlm.nih.gov/14513875","citation_count":22,"is_preprint":false},{"pmid":"26631348","id":"PMC_26631348","title":"Profiling of conserved non-coding elements upstream of SHOX and functional characterisation of the SHOX cis-regulatory landscape.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26631348","citation_count":21,"is_preprint":false},{"pmid":"10626546","id":"PMC_10626546","title":"SHOX gene mutations and deletions in dyschondrosteosis or Leri-Weill syndrome.","date":"1999","source":"Acta paediatrica (Oslo, Norway : 1992). Supplement","url":"https://pubmed.ncbi.nlm.nih.gov/10626546","citation_count":21,"is_preprint":false},{"pmid":"27861128","id":"PMC_27861128","title":"Retinoic acid catabolizing enzyme CYP26C1 is a genetic modifier in SHOX deficiency.","date":"2016","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27861128","citation_count":20,"is_preprint":false},{"pmid":"36114168","id":"PMC_36114168","title":"WRN promotes bone development and growth by unwinding SHOX-G-quadruplexes via its helicase activity in Werner Syndrome.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36114168","citation_count":20,"is_preprint":false},{"pmid":"26264720","id":"PMC_26264720","title":"The growth response to GH treatment is greater in patients with SHOX enhancer deletions compared to SHOX defects.","date":"2015","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/26264720","citation_count":20,"is_preprint":false},{"pmid":"30250174","id":"PMC_30250174","title":"Identification of a limb enhancer that is removed by pathogenic deletions downstream of the SHOX gene.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30250174","citation_count":19,"is_preprint":false},{"pmid":"12784295","id":"PMC_12784295","title":"Deletion of the SHOX gene in patients with short stature of unknown cause.","date":"2003","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/12784295","citation_count":19,"is_preprint":false},{"pmid":"20538086","id":"PMC_20538086","title":"Usefulness of MLPA in the detection of SHOX deletions.","date":"2010","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20538086","citation_count":19,"is_preprint":false},{"pmid":"23575226","id":"PMC_23575226","title":"Comparative transgenic analysis of enhancers from the human SHOX and mouse Shox2 genomic regions.","date":"2013","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23575226","citation_count":19,"is_preprint":false},{"pmid":"24689071","id":"PMC_24689071","title":"SHOX gene and conserved noncoding element deletions/duplications in Colombian patients with idiopathic short stature.","date":"2013","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24689071","citation_count":18,"is_preprint":false},{"pmid":"24248941","id":"PMC_24248941","title":"Replacing Shox2 with human SHOX leads to congenital disc degeneration of the temporomandibular joint in mice.","date":"2013","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/24248941","citation_count":18,"is_preprint":false},{"pmid":"20432819","id":"PMC_20432819","title":"Unexpected phenotype in a boy with trisomy of the SHOX gene.","date":"2010","source":"Journal of pediatric endocrinology & metabolism : JPEM","url":"https://pubmed.ncbi.nlm.nih.gov/20432819","citation_count":18,"is_preprint":false},{"pmid":"11889214","id":"PMC_11889214","title":"SHOX nullizygosity and haploinsufficiency in a Japanese family: implication for the development of Turner skeletal features.","date":"2002","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/11889214","citation_count":18,"is_preprint":false},{"pmid":"12402330","id":"PMC_12402330","title":"The human SHOX mutation database.","date":"2002","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/12402330","citation_count":17,"is_preprint":false},{"pmid":"23208451","id":"PMC_23208451","title":"Impaired GH secretion in patients with SHOX deficiency and efficacy of recombinant human GH therapy.","date":"2012","source":"Hormone research in paediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/23208451","citation_count":17,"is_preprint":false},{"pmid":"17394206","id":"PMC_17394206","title":"Compound heterozygosity of SHOX-encompassing and downstream PAR1 deletions results in Langer mesomelic dysplasia (LMD).","date":"2007","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/17394206","citation_count":17,"is_preprint":false},{"pmid":"18322641","id":"PMC_18322641","title":"Identification and characterization of cryptic SHOX intragenic deletions in three Japanese patients with Léri-Weill dyschondrosteosis.","date":"2008","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18322641","citation_count":17,"is_preprint":false},{"pmid":"17726696","id":"PMC_17726696","title":"The novel human SHOX allelic variant database.","date":"2007","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/17726696","citation_count":16,"is_preprint":false},{"pmid":"25483930","id":"PMC_25483930","title":"In vivo loss of function study reveals the short stature homeobox-containing (shox) gene plays indispensable roles in early embryonic growth and bone formation in zebrafish.","date":"2014","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/25483930","citation_count":16,"is_preprint":false},{"pmid":"25967354","id":"PMC_25967354","title":"Radiological Features in Patients with Short Stature Homeobox-Containing (SHOX) Gene Deficiency and Turner Syndrome before and after 2 Years of GH Treatment.","date":"2015","source":"Hormone research in paediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/25967354","citation_count":16,"is_preprint":false},{"pmid":"31834863","id":"PMC_31834863","title":"Pathogenic/likely pathogenic variants in the SHOX, GHR and IGFALS genes among Indian children with idiopathic short stature.","date":"2020","source":"Journal of pediatric endocrinology & metabolism : JPEM","url":"https://pubmed.ncbi.nlm.nih.gov/31834863","citation_count":16,"is_preprint":false},{"pmid":"11408757","id":"PMC_11408757","title":"SHOX in short stature syndromes.","date":"2001","source":"Hormone research","url":"https://pubmed.ncbi.nlm.nih.gov/11408757","citation_count":15,"is_preprint":false},{"pmid":"24887312","id":"PMC_24887312","title":"Identification of novel SHOX target genes in the developing limb using a transgenic mouse model.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24887312","citation_count":15,"is_preprint":false},{"pmid":"28642734","id":"PMC_28642734","title":"The Short-Stature Homeobox-Containing Gene (shox/SHOX) Is Required for the Regulation of Cell Proliferation and Bone Differentiation in Zebrafish Embryo and Human Mesenchymal Stem Cells.","date":"2017","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/28642734","citation_count":14,"is_preprint":false},{"pmid":"19016538","id":"PMC_19016538","title":"SHOX gene is expressed in vertebral body growth plates in idiopathic and congenital scoliosis: implications for the etiology of scoliosis in Turner syndrome.","date":"2009","source":"Journal of orthopaedic research : official publication of the Orthopaedic Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/19016538","citation_count":14,"is_preprint":false},{"pmid":"24051572","id":"PMC_24051572","title":"Short stature before puberty: which children should be screened for SHOX deficiency?","date":"2013","source":"Hormone research in paediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/24051572","citation_count":14,"is_preprint":false},{"pmid":"23638371","id":"PMC_23638371","title":"Phenotypic characterization of patients with deletions in the 3'-flanking SHOX region.","date":"2013","source":"PeerJ","url":"https://pubmed.ncbi.nlm.nih.gov/23638371","citation_count":14,"is_preprint":false},{"pmid":"32647378","id":"PMC_32647378","title":"Variants in the 5'UTR reduce SHOX expression and contribute to SHOX haploinsufficiency.","date":"2020","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/32647378","citation_count":13,"is_preprint":false},{"pmid":"32518174","id":"PMC_32518174","title":"Rare and de novo duplications containing SHOX in clubfoot.","date":"2020","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32518174","citation_count":13,"is_preprint":false},{"pmid":"24008148","id":"PMC_24008148","title":"Y-chromosome microdeletions are not associated with SHOX haploinsufficiency.","date":"2013","source":"Human reproduction (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/24008148","citation_count":13,"is_preprint":false},{"pmid":"25220427","id":"PMC_25220427","title":"Increased cortical area and thickness in the distal radius in subjects with SHOX-gene mutation.","date":"2014","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/25220427","citation_count":13,"is_preprint":false},{"pmid":"27814343","id":"PMC_27814343","title":"Prevalence of SHOX haploinsufficiency among short statured children.","date":"2016","source":"Pediatric research","url":"https://pubmed.ncbi.nlm.nih.gov/27814343","citation_count":13,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50012,"output_tokens":5535,"usd":0.11653,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14068,"output_tokens":5155,"usd":0.099608,"stage2_stop_reason":"end_turn"},"total_usd":0.216138,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"SHOX (alias PHOG) encodes a homeodomain-containing transcription factor expressed at highest levels in osteogenic cells; the gene resides in the pseudoautosomal region PAR1 of the sex chromosomes and escapes X inactivation, establishing dosage-sensitive expression relevant to stature.\",\n      \"method\": \"Positional cloning, expression analysis in osteogenic cells, X-inactivation assay\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — positional cloning plus expression characterization in a single lab, multiple methods but no functional reconstitution\",\n      \"pmids\": [\"9259282\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"SHOX protein localizes exclusively to the nucleus in multiple cell lines (U2Os, HEK293, COS7, NIH 3T3), and functions as a cell-type-specific transcriptional activator: transactivation of luciferase reporter constructs was detected only in the osteogenic U2Os line. C-terminally truncated SHOX proteins (as found in Leri-Weill syndrome patients) are inactive for target gene activation.\",\n      \"method\": \"Stable cell-line transfection, luciferase reporter assays, nuclear localization by immunofluorescence, truncation mutant analysis\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal reporter assays plus localization experiments, multiple cell lines, mutagenesis of disease-relevant truncations, single lab\",\n      \"pmids\": [\"11751690\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"SHOX expression is regulated by a combination of transcriptional and translational control: an alternative internal promoter (P2) within exon 2 drives efficiently translated mRNA, while the upstream promoter (P1) produces mRNA with seven upstream AUG codons (uAUGs) that strongly inhibit translation. Site-directed mutagenesis of these uAUGs fully restores translation efficiency in cell lines and Xenopus embryos.\",\n      \"method\": \"Transient transfection of mono- and bicistronic reporters, in vitro translation assays, direct mRNA transfection, site-directed mutagenesis, Xenopus embryo injection\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro translation reconstitution plus mutagenesis and in vivo (Xenopus) validation, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"12960152\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"SHOX expression in osteogenic cell lines, primary oral fibroblasts, and primary chondrocytes induces cell cycle arrest and apoptosis, associated with altered expression of pRB, p53, p21(Cip1) and p27(Kip1). A disease-associated SHOX mutant (from Leri-Weill patients) does not exhibit these activities. Endogenous SHOX protein is predominantly expressed in hypertrophic/apoptotic chondrocytes of the human growth plate.\",\n      \"method\": \"Stable transfection in cell lines and primary cells, flow cytometry (cell cycle), apoptosis assays, Western blotting of cell cycle regulators, immunohistochemistry of human growth plate\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function-equivalent mutant comparison, multiple cell types, growth plate localization with functional consequence, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"15145945\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"The nuclear localization signal (NLS) of SHOX was mapped to a non-classic basic motif AKCRK in the recognition helix of the homeodomain. Fusion of this pentapeptide to a cytoplasmic reporter protein is sufficient to drive nuclear translocation. A disease-associated missense mutation R173C (C517T) abolishes nuclear entry; insertion of the NLS sequence adjacent to the mutant site restores translocation.\",\n      \"method\": \"Deletion mapping, NLS-reporter fusion constructs, immunofluorescence, mutagenesis of R173C, NLS rescue experiment\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — domain mapping by deletion, functional reconstitution with rescue mutagenesis, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"15173321\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Nine homeodomain missense mutations found in ISS/LWD patients impair SHOX function through loss of DNA binding, reduced dimerization ability, and/or impaired nuclear translocation. One mutation (R153L) retains DNA binding, dimerization, and nuclear entry but is defective in transcriptional activation, defining a separable transactivation function.\",\n      \"method\": \"Electrophoretic mobility shift assay (DNA binding), co-immunoprecipitation (dimerization), immunofluorescence (nuclear translocation), luciferase reporter assay (transactivation), mutagenesis panel\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple biochemical assays (EMSA, Co-IP, reporter) applied to nine independent mutations in a single systematic study\",\n      \"pmids\": [\"15931687\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"In chicken limb buds, Shox expression is restricted to the central/proximal regions; it is repressed distally by FGF and BMP signals from the apical ectodermal ridge and proximally by retinoic acid signaling. Viral overexpression of Shox in chicken limbs consistently increases the length of skeletal elements, and micromass cultures show an initial increase in cartilage nodule number but failure to enlarge.\",\n      \"method\": \"In situ hybridization, retroviral overexpression in chicken embryos, micromass cultures, skeletal staining\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain-of-function in vivo with skeletal phenotype readout, pathway placement via signaling inhibition, single lab, multiple complementary methods\",\n      \"pmids\": [\"16904661\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"NPPB (encoding BNP, natriuretic peptide B) is a direct transcriptional target of SHOX. SHOX transactivates the endogenous NPPB promoter in luciferase assays; chromatin immunoprecipitation (ChIP) confirmed SHOX binding to the NPPB promoter in vivo. Two LWD-associated SHOX mutants fail to activate the promoter. BNP and SHOX are co-expressed in late proliferative and hypertrophic chondrocytes of the human growth plate.\",\n      \"method\": \"Luciferase reporter assay with serial NPPB promoter deletions, chromatin immunoprecipitation (ChIP), mutant SHOX functional comparison, immunohistochemistry\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vivo ChIP plus reporter assay plus disease-mutant validation, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"17881654\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Conserved non-coding elements (CNEs) located ~48–215 kb downstream of SHOX function as cis-regulatory enhancers active in the developing chicken limb bud; in ovo electroporation of GFP reporter constructs driven by individual CNEs demonstrated enhancer activity in three of eight tested elements. Deletion of this region in patients produces an LWD phenotype identical to SHOX coding mutations.\",\n      \"method\": \"In ovo electroporation enhancer assay in chicken limb bud (GFP reporter), comparative genomics, SNP/FISH mapping of patient deletions\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct in vivo enhancer assay with reporter, correlated with human disease deletions, single lab\",\n      \"pmids\": [\"17200153\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Three conserved non-coding elements upstream of SHOX have enhancer activity in the developing chicken limb bud (in ovo electroporation assay) but not in the developing cornea, defining tissue-specific upstream regulatory elements for SHOX.\",\n      \"method\": \"In ovo electroporation enhancer assay in chicken limb bud and cornea, comparative genomic analysis\",\n      \"journal\": \"European journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct in vivo enhancer assay, two tissue types tested, single lab\",\n      \"pmids\": [\"19997128\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"SHOX physically interacts with the chondrogenic transcription factors SOX5 and SOX6, identified by yeast two-hybrid screen and confirmed by co-immunoprecipitation in human cells. The SHOX homeodomain and SOX6 HMG domain mediate the interaction. Disease-associated SHOX missense mutations disrupt the interaction. SHOX cooperates with SOX5/SOX6 and SOX9 to activate the upstream Agc1 (aggrecan) enhancer; SHOX mutations impair this cooperative activation.\",\n      \"method\": \"Yeast two-hybrid screen, co-immunoprecipitation, domain mapping, luciferase reporter assay (Agc1 enhancer), immunohistochemistry of human fetal growth plate, disease-mutant panel\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, domain mapping, functional reporter, disease-mutant validation, growth plate co-expression, multiple orthogonal methods\",\n      \"pmids\": [\"21262861\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"SHOX activates FGFR3 promoter in luciferase reporter assays; ChIP-sequencing and EMSA demonstrated direct binding of SHOX to multiple upstream sequences of FGFR3. In chicken micromass cultures, viral overexpression of Shox negatively regulates Fgfr3 (quantitative RT-PCR and in situ hybridization), suggesting that SHOX represses FGFR3 in the mesomelic limb segments.\",\n      \"method\": \"Microarray analysis, luciferase reporter assay, ChIP-sequencing, EMSA, viral overexpression in chicken micromass cultures, qRT-PCR, in situ hybridization\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro binding (EMSA), ChIP-seq, functional reporter, and in vivo chicken model, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"21273290\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Human SHOX and mouse Shox2 share functional redundancy in sinoatrial node (SAN) development: both show similar transcriptional repressive activity on the Nkx2.5 promoter in cell culture. In SHOX/Shox2 knock-in mice (Shox2 replaced by human SHOX), SAN formation and pacemaking function are fully restored, demonstrating that SHOX can repress Nkx2.5-driven SAN differentiation pathways.\",\n      \"method\": \"Luciferase reporter assay (Nkx2.5 promoter repression), SHOX/Shox2 knock-in mouse model, physiological/histological/molecular analysis of SAN\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — genetic knock-in rescue in vivo plus in vitro reporter assay, single lab but rigorous in vivo rescue design\",\n      \"pmids\": [\"21454626\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Alternative splicing coupled with nonsense-mediated RNA decay (NMD) regulates SHOX expression levels in a tissue- and time-specific manner. Inclusion of novel exon 2a introduces a premature stop codon leading to NMD; four novel exons (2a, 7-1, 7-2, 7-3) were identified. Exon 7 variants are exclusively expressed in fetal neural tissues.\",\n      \"method\": \"RT-PCR, RNA-Seq, functional analysis of exon 2a by minigene/NMD reporter, tissue expression profiling\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional NMD assay plus expression profiling across tissues, single lab\",\n      \"pmids\": [\"21448463\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"SHOX triggers apoptosis via oxidative stress leading to lysosomal membrane rupture, release of active cathepsin B to the cytosol, mitochondrial membrane permeabilization, and caspase activation (intrinsic apoptotic pathway). LWD-associated mutants SHOX R153L and SHOX L185X (C-terminal truncation) do not induce oxidative stress or any of these downstream apoptotic events.\",\n      \"method\": \"ROS measurement, lysosomal integrity assays, cathepsin B activity assay, mitochondrial membrane potential assay, caspase activity assay, stable transfection of wild-type vs. mutant SHOX in U2OS cells\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mechanistic dissection of apoptotic pathway with multiple biochemical readouts, disease mutant validation, single lab\",\n      \"pmids\": [\"24186869\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"In a Col2a1-SHOX transgenic mouse, human SHOXa regulates extracellular matrix gene expression during early limb development, including transcriptional activation of Ctgf (connective tissue growth factor). This was confirmed in human NHDF and U2OS cells and chicken micromass culture.\",\n      \"method\": \"Transgenic mouse (Col2a1-SHOX), quantitative and in situ hybridization analyses, confirmation in human cell lines and chicken micromass culture\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo transgenic model plus cell culture confirmation in multiple systems, single lab\",\n      \"pmids\": [\"24887312\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Zebrafish shox loss-of-function (morpholino knockdown) delays embryonic growth and markedly impairs calcification of the anterior vertebral column and craniofacial bones. The growth delay phenotype is rescued by co-overexpression of morpholino-resistant Shox mRNA, confirming specificity.\",\n      \"method\": \"Antisense morpholino knockdown in zebrafish, skeletal staining, mRNA rescue experiment\",\n      \"journal\": \"Developmental dynamics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo loss-of-function with rescue in zebrafish, single lab\",\n      \"pmids\": [\"25483930\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CYP26C1 (a retinoic acid catabolizing enzyme) is a genetic modifier of SHOX deficiency. CYP26C1 variants reduce its catabolic activity, elevating retinoic acid levels, which significantly decrease SHOX expression in human primary chondrocytes and zebrafish embryos. In zebrafish, individual morpholino knockdown of either shox or cyp26c1 shortens pectoral fins; combined knockdown produces a more severe phenotype, establishing epistasis.\",\n      \"method\": \"CYP26C1 enzymatic activity assay, SHOX expression in human primary chondrocytes with retinoic acid treatment, zebrafish morpholino knockdown (single and double), pectoral fin length measurement, family genetic co-segregation\",\n      \"journal\": \"EMBO molecular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — enzymatic assay, in vitro expression assay, genetic epistasis in vivo (zebrafish double knockdown), plus human family co-segregation, multiple orthogonal approaches\",\n      \"pmids\": [\"27861128\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"A 563 bp enhancer downstream of SHOX drives specific expression in the zeugopodal limb regions where SHOX is required; a primary cell luciferase assay confirmed enhancer activity, and putative HOX binding sites within the conserved 100 bp core are required for its activity. This enhancer is removed in most non-coding PAR1 deletions that cause LWD.\",\n      \"method\": \"Transgenic mouse enhancer assay, luciferase reporter assay, HOX binding site mutagenesis, deletion mapping against LWD patient cohort\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vivo transgenic reporter plus mutagenesis of binding sites plus cell-based reporter, single lab\",\n      \"pmids\": [\"30250174\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"5'UTR variants (c.-51G>A, c.-19G>A, c.-9del) reduce SHOX expression and contribute to haploinsufficiency. Luciferase assays showed c.-51G>A and c.-9del reduce activity at the post-transcriptional level; a minigene splicing assay demonstrated that c.-19G>A creates an aberrant branch site causing mis-splicing of SHOX mRNA.\",\n      \"method\": \"Luciferase reporter assay (5'UTR variants), luciferase mRNA quantification, minigene exon-trapping splicing assay\",\n      \"journal\": \"European journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional reporter plus splicing assay, two orthogonal methods, single lab\",\n      \"pmids\": [\"32647378\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"WRN helicase domain directly regulates SHOX transcription by unwinding G-quadruplex structures in the SHOX locus. WRN-null zebrafish (wrn-/-) show impaired bone growth and shorter stature; shox-/- zebrafish exhibit the same phenotype; genetic overexpression of SHOX/shox rescues bone developmental deficiency in WRN/wrn-null animals both in vitro and in vivo.\",\n      \"method\": \"Zebrafish genetic knockout (wrn-/-, shox-/-), G-quadruplex unwinding assay (helicase assay), genetic rescue by SHOX overexpression in vitro and in vivo\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro helicase assay plus in vivo genetic epistasis rescue in zebrafish, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"36114168\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SHOX encodes a paired-related homeodomain transcription factor that resides in PAR1 of the sex chromosomes, localizes to the nucleus via an AKCRK NLS in its homeodomain recognition helix, and functions as a cell-type-specific transcriptional activator (and in some contexts repressor) regulating chondrocyte differentiation: it directly activates targets including BNP/NPPB, Agc1 (in cooperation with SOX5/SOX6/SOX9), CTGF, and FGFR3, while repressing Nkx2.5; in hypertrophic growth-plate chondrocytes it induces apoptosis via oxidative stress → lysosomal membrane permeabilization → cathepsin B release → intrinsic caspase pathway; its expression is controlled by dual promoters with upstream uAUG-mediated translational repression, by alternative splicing/NMD, by downstream and upstream cis-regulatory enhancers (including HOX-site-dependent elements), and by WRN helicase-mediated resolution of G-quadruplexes at the locus, with retinoic acid levels (modulated by CYP26C1) acting as a genetic modifier of SHOX expression level.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"SHOX encodes a paired-related homeodomain transcription factor that governs chondrocyte differentiation and skeletal growth, residing in the pseudoautosomal region PAR1 where it escapes X-inactivation to give dosage-sensitive expression relevant to stature [#0]. The protein localizes exclusively to the nucleus via a non-classic basic AKCRK motif in the homeodomain recognition helix, and functions as a cell-type-specific transcriptional activator whose disease-associated mutations impair DNA binding, dimerization, nuclear entry, or a separable transactivation function [#1, #4, #5]. SHOX directly activates a chondrogenic target program, binding and transactivating the NPPB/BNP promoter, cooperating with SOX5/SOX6/SOX9 at the Agc1 (aggrecan) enhancer through a homeodomain\\u2013HMG-domain interaction, regulating FGFR3 and the extracellular-matrix gene Ctgf, and acting as a repressor of Nkx2.5 in sinoatrial node development \\u2014 a role rescued by human SHOX in Shox2 knock-in mice [#7, #10, #11, #12, #15]. In hypertrophic growth-plate chondrocytes, where endogenous SHOX is concentrated, it drives cell-cycle arrest and an intrinsic apoptotic program proceeding through oxidative stress, lysosomal membrane rupture, cathepsin B release, and caspase activation [#3, #14]. SHOX expression is itself tightly controlled by dual promoters with uAUG-mediated translational repression, alternative splicing coupled to NMD, downstream and upstream limb-specific enhancers requiring HOX binding sites, WRN-helicase resolution of locus G-quadruplexes, and retinoic acid levels set by the genetic modifier CYP26C1 [#2, #8, #13, #17, #18, #20]. Loss of SHOX function causes Leri-Weill dyschondrosteosis and idiopathic short stature, as established by recurrent coding and non-coding deletions and functionally null mutations [#1, #8, #18].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Established the identity and genomic context of SHOX, linking a homeodomain transcription factor in PAR1 that escapes X-inactivation to dosage-sensitive control of stature.\",\n      \"evidence\": \"Positional cloning, osteogenic expression analysis, and X-inactivation assay\",\n      \"pmids\": [\"9259282\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No target genes or biochemical activity defined\", \"Functional reconstitution absent\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Showed SHOX is a nuclear, cell-type-restricted transcriptional activator and that Leri-Weill truncations abolish target activation, tying the protein's transactivation to disease.\",\n      \"evidence\": \"Luciferase reporter assays, immunofluorescence, and truncation mutant analysis across multiple cell lines\",\n      \"pmids\": [\"11751690\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct target genes not yet identified\", \"Basis of cell-type specificity unresolved\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Defined translational and promoter-level control: a P2 promoter yields efficiently translated mRNA whereas P1 transcripts are repressed by upstream AUG codons.\",\n      \"evidence\": \"Reporter and in vitro translation assays with uAUG mutagenesis, validated in Xenopus embryos\",\n      \"pmids\": [\"12960152\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological trigger selecting promoter/translation usage unknown\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Connected SHOX to growth-plate biology by showing it drives cell-cycle arrest and apoptosis in chondrocytes and is concentrated in hypertrophic chondrocytes.\",\n      \"evidence\": \"Stable transfection, flow cytometry, apoptosis assays, cell-cycle regulator Westerns, and growth-plate IHC, with disease-mutant comparison\",\n      \"pmids\": [\"15145945\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular pathway from SHOX to apoptosis not yet defined\", \"Direct apoptotic target genes unknown\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Mapped the nuclear localization signal to the AKCRK motif in the recognition helix and showed a disease mutation (R173C) blocks nuclear entry, explaining one mutational mechanism.\",\n      \"evidence\": \"Deletion mapping, NLS-reporter fusions, immunofluorescence, and rescue mutagenesis\",\n      \"pmids\": [\"15173321\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Import receptor mediating non-classic NLS recognition unidentified\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Systematically resolved how homeodomain mutations cause haploinsufficiency \\u2014 via lost DNA binding, dimerization, or nuclear entry \\u2014 and isolated a transactivation-specific defect (R153L).\",\n      \"evidence\": \"EMSA, co-immunoprecipitation, immunofluorescence, and reporter assays across nine patient mutations\",\n      \"pmids\": [\"15931687\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transactivation cofactors at R153L-affected step not identified\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Placed Shox in limb patterning, showing its expression is bounded by FGF/BMP and retinoic acid signals and that overexpression lengthens skeletal elements.\",\n      \"evidence\": \"In situ hybridization, retroviral overexpression, and micromass culture in chicken\",\n      \"pmids\": [\"16904661\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct transcriptional targets mediating elongation not defined\", \"Mammalian relevance not addressed\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identified NPPB/BNP as a direct SHOX target, providing the first validated transcriptional target with growth-plate co-expression.\",\n      \"evidence\": \"Promoter-deletion luciferase assays, ChIP, disease-mutant comparison, and IHC\",\n      \"pmids\": [\"17881654\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Role of BNP induction in chondrocyte fate not functionally tested\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Demonstrated that downstream conserved non-coding elements act as limb enhancers and that their deletion phenocopies coding mutations, defining non-coding disease mechanisms.\",\n      \"evidence\": \"In ovo electroporation enhancer assays and mapping of patient deletions\",\n      \"pmids\": [\"17200153\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Trans-factors binding the enhancers not identified\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Extended the regulatory landscape upstream, showing tissue-specific upstream enhancers active in limb but not cornea.\",\n      \"evidence\": \"In ovo electroporation enhancer assays in two tissues\",\n      \"pmids\": [\"19997128\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Endogenous contribution and bound factors undetermined\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Revealed how SHOX is integrated into the chondrogenic network, physically partnering with SOX5/SOX6 and cooperating with SOX9 to activate the Agc1 enhancer.\",\n      \"evidence\": \"Yeast two-hybrid, reciprocal Co-IP, domain mapping, Agc1 reporter, IHC, and disease-mutant panel\",\n      \"pmids\": [\"21262861\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genome-wide co-occupancy with SOX factors not mapped\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Established FGFR3 as a directly bound SHOX target, linking SHOX to a key growth-plate signaling receptor in mesomelic segments.\",\n      \"evidence\": \"Microarray, reporter assay, ChIP-seq, EMSA, and chicken micromass overexpression\",\n      \"pmids\": [\"21273290\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Activation versus repression context dependence not fully resolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Showed SHOX represses Nkx2.5 and is functionally interchangeable with Shox2 in sinoatrial node development, defining a repressor activity and conserved function outside the skeleton.\",\n      \"evidence\": \"Nkx2.5 reporter repression assay and SHOX/Shox2 knock-in mouse rescue\",\n      \"pmids\": [\"21454626\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether native human SHOX functions in cardiac tissue physiologically untested\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Added post-transcriptional control by alternative splicing coupled to NMD, including a tissue-specific exon 2a that triggers decay.\",\n      \"evidence\": \"RT-PCR, RNA-Seq, minigene/NMD reporter, and tissue profiling\",\n      \"pmids\": [\"21448463\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Regulatory inputs controlling splice-choice not identified\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Dissected the SHOX apoptotic pathway as oxidative stress \\u2192 lysosomal rupture \\u2192 cathepsin B release \\u2192 mitochondrial permeabilization \\u2192 caspase activation, with disease mutants failing at the first step.\",\n      \"evidence\": \"ROS, lysosomal integrity, cathepsin B, mitochondrial potential, and caspase assays with WT vs mutant SHOX in U2OS\",\n      \"pmids\": [\"24186869\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"SHOX transcriptional targets that initiate oxidative stress unknown\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identified Ctgf as a SHOX-regulated extracellular matrix gene in vivo, broadening the target repertoire to ECM organization.\",\n      \"evidence\": \"Col2a1-SHOX transgenic mouse with confirmation in human cells and chicken micromass\",\n      \"pmids\": [\"24887312\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct versus indirect regulation of Ctgf not distinguished\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Confirmed an evolutionarily conserved requirement for shox in skeletal calcification through loss-of-function in zebrafish.\",\n      \"evidence\": \"Morpholino knockdown with mRNA rescue and skeletal staining\",\n      \"pmids\": [\"25483930\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Morpholino-only knockdown without genetic mutant\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defined CYP26C1 as a genetic modifier acting through retinoic acid, where reduced RA catabolism lowers SHOX expression and worsens skeletal phenotypes.\",\n      \"evidence\": \"Enzymatic assays, RA treatment of human chondrocytes, zebrafish single/double knockdown epistasis, and family co-segregation\",\n      \"pmids\": [\"27861128\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcription factors transducing RA signal onto SHOX promoter unidentified\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Localized a 563 bp downstream limb enhancer whose HOX binding sites are required and whose loss in PAR1 deletions causes LWD, refining the regulatory disease map.\",\n      \"evidence\": \"Transgenic mouse and cell reporter assays, HOX-site mutagenesis, and deletion mapping in patients\",\n      \"pmids\": [\"30250174\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific HOX factors binding the core not identified\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showed 5'UTR variants reduce SHOX expression post-transcriptionally or via aberrant splicing, expanding mechanisms of haploinsufficiency.\",\n      \"evidence\": \"Luciferase reporter, mRNA quantification, and minigene splicing assays\",\n      \"pmids\": [\"32647378\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Endogenous quantitative impact on stature not measured\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Linked WRN helicase to SHOX transcription by resolving locus G-quadruplexes, with SHOX overexpression rescuing WRN-null skeletal defects, placing SHOX downstream of WRN in bone growth.\",\n      \"evidence\": \"In vitro G-quadruplex unwinding assay and zebrafish wrn-/-, shox-/- epistasis with genetic rescue\",\n      \"pmids\": [\"36114168\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether WRN-SHOX axis operates in human growth plate not shown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How SHOX selects between activator and repressor modes, and the full identity of its cofactor-dependent target program in human hypertrophic chondrocytes, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No genome-wide SHOX occupancy map in human chondrocytes\", \"Switch between transactivation and repression not mechanistically defined\", \"Apoptosis-initiating target genes unidentified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [1, 7, 10, 11, 12]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [5, 7, 11]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [7, 11, 12]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [6, 8, 16, 18]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [3, 14]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"SOX5\", \"SOX6\", \"SOX9\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}